Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
Codexis (CDXS) has entered into a partnership with an unnamed leading developer of small interfering RNA (siRNA) therapeutics to assess the application of its ECO Synthesis platform in manufacturing stereo-defined oligonucleotides. The collaboration aims to leverage Codexis' proprietary StereoSelect technology, which enables precise control over stereochemistry during synthesis. This strategic move is intended to enhance the production capabilities for RNA-based therapies by offering a more efficient and scalable enzymatic approach. Such advancements could potentially improve drug development timelines and reduce manufacturing costs in the oligonucleotide space.
Tickers: $CDXS
Topics: biotech RNA manufacturing stereochemistry synthesis platform